Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Activity In Emerging Markets Deemed Minor Against Global Backdrop - ACRO

This article was originally published in PharmAsia News

Executive Summary

The Association of Clinical Research Organizations is distancing itself from a notion that a "high degree" of clinical trial work is conducted in emerging markets

You may also be interested in...



Will Spiraling Costs Retard Growth Of Clinical Research In India? The Jury Is Out

MUMBAI - From being a preferred destination for conducting clinical research to facing competitive pressure from countries like Malaysia, the Indian clinical research industry may miss the opportunity of emerging as a global hub for multinational drug companies

Will Spiraling Costs Retard Growth Of Clinical Research In India? The Jury Is Out

MUMBAI - From being a preferred destination for conducting clinical research to facing competitive pressure from countries like Malaysia, the Indian clinical research industry may miss the opportunity of emerging as a global hub for multinational drug companies

Clinical Research Is Booming In India But Are There Enough IRBs?

MUMBAI - Over the past decade, India's clinical research industry has grown at a compound annual rate of 64 percent, zooming up from just $12 million in 2001 to an estimated billion-plus dollars by next year. But that meteoric rise may be putting pressure on Institutional Review Boards entrusted with approval of clinical trials and some industry experts are now asking for better controls over IRBs, or ethics review boards

Related Content

UsernamePublicRestriction

Register

SC072259

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel